A CASE STUDY

ON
THE STRUCTURAL
EVOLUTION OF BIOCON
Presented By
Sabyasachi Nanda
Suman Sourav Patra
Ishan Kumar Naik
Sohani Kar
Jaya Satapathy
Jajatikesari Sethy
Rakesh Kumar jha
 INTRODUCTION
 Biocon, the global health care company, is the India’s leading
bio-technology company based in Bangalore.
 Biocon was founded in 1978 with ₹10,000 as the initial capital.
 The Company manufactures generic active pharmaceutical
ingredients that are sold in over 120 countries, including USA
and Europe.
 Biocon's formulations for the Indian market include
Metabolics, Oncology, Immunotherapy, Nephrology and
Specialty.
 1st biotechnological company to receive ISO 9001 certification in
India.
 It has been ranked 1st in Asia and 16th in the world.
 Subsidiaries: - Syngene and Clinigene
 The lady behind the entire success: - Mrs. Kiran Majumdar Shaw.
 STRUCTURAL DIMESIONS

Formalization : - Low
Specialization: - High
Centralization: - High

Strengths
 Growth in Net Profit with
increasing Profit Margin (QoQ).
 Increasing Revenue every
quarter for the past 2 quarters.
 Improving Cash Flow from
operation for last 2 years.
 Company with Low Debt
 Increasing profits every
quarter for the past 2 quarters.
 Company with Zero
Promoter Pledge.
SWOT ANALYSIS
Weaknesses Opportunities Threats
 MFs decreased their  Rising Delivery Stocks with high
shareholding last quarter. Percentage Compared to Price Earning (PE >
Previous Day and Month, 40)
Strong Volumes.
 Declining Net Cash Flow :  Brokers upgraded
Companies not able to recommendation or target
generate net cash. price in the past three
months.
 Decline in Quarterly Net
Profit with falling Profit
Margin (YoY).
 Recent Results: Declining
Operating Profit Margin and
Net Profits (YoY).
CORPORATE STRUCTURE OF
BIOCON LIMITED
ORGANIZATIONAL STRUCTURE OF BIOCON
LIMITED
CONCLUSION